首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study
【24h】

Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study

机译:替莫唑胺类负载纳米脂质基壳聚糖水凝胶鼻递送至脑递送:表征,鼻腔吸收,组织病理学和细胞系研究

获取原文
获取原文并翻译 | 示例
       

摘要

The present study was designed to develop and optimize Temozolomide nano lipid chitosan hydrogel formulations (TMZNLCHG) to target the brain through nasal route. The formulation was developed using chitosan as a gelling agent and Vit E: gelucire 44/14 blend as lipid. The formulations were evaluated for particle size, encapsulation efficiency (%EE), drug loading (DL), morphology, drug release, nasal diffusion, cell line study, and histopathology study. The particle size, PDI, %EE, %DL, and drug release were found to be 134 nm, 0.177, 88.45% +/- 4.45%, 9.12% +/- 0.78%, and 84.23% +/- 2.78%, respectively. The enhancement ratio was more than two folds higher than TMZCHG formulation (control) suggesting the superiority of chitosan with lipid as permeability enhancer. The microscopic image of lyophilized TMZNLCHGopt displayed the spherical and rough surface morphology. IC50 was found to be 334 mu g/ml for TMZNLCHGopt and was 160 mu g/ml for pure TMZ. Further, No structural damage was observed with TMZNLCHGopt treated nasal mucosa upon histopathological examination. Overall, the present study produces encouraging findings in the formulation of a non-invasive intranasal route for brain targeting as an alternate to other route for TMZ. (C) 2018 Elsevier B.V. All rights reserved.
机译:本研究旨在开发和优化替替唑胺纳米脂壳聚糖水凝胶制剂(TMZNLCHG)以通过鼻途径靶向脑。使用壳聚糖作为胶凝剂和Vit E:Gelucire 44/14混合作为脂质的制剂。评价制剂用于粒度,包封效率(%EE),药物负载(DL),形态,药物释放,鼻扩散,细胞系研究和组织病理学研究。发现粒径,PDI,%EE,%DL和药物释放为134nm,0.177,88.45%+/- 4.45%,9.12%+/- 0.78%,分别为84.23%+/- 2.78% 。增强比率高于Tmzchg制剂(对照)的两倍以上,表明壳聚糖与脂质作为渗透性增强剂的优越性。冻干Tmznlchgopt的微观图像显示球形和粗糙表面形态。发现IC 50为TmZnlchgopt为334μg/ ml,纯TMZ为160μg/ ml。此外,在组织病理学检查时,TMZNLCHGopt处理的鼻粘膜没有观察到结构损伤。总体而言,本研究产生令人令人抱怨的表明在制定脑靶向的非侵入性鼻内途径,作为TMZ的其他途径的替代品。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号